Track all markets on TradingView
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts
Media

Evaluating Pacira BioSciences: Insights From 8 Financial Analysts

  • November 7, 2024
  • 20 Views

Latest Ratings for PCRX

Date Firm Action From To
Feb 2022 Wedbush Maintains Outperform
Feb 2022 HC Wainwright & Co. Maintains Buy
Jan 2022 Barclays Maintains Overweight

View More Analyst Ratings for PCRX

View the Latest Analyst Ratings

read more

​ 

​Latest Ratings for PCRX
DateFirmActionFromTo Feb 2022WedbushMaintainsOutperform Feb 2022HC Wainwright & Co.MaintainsBuy Jan 2022BarclaysMaintainsOverweight
View More Analyst Ratings for PCRX

View the Latest Analyst Ratings

read more 

Share This Post:

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.